The International immunosuppression & Transplant Skin Cancer Collaborative (ITSCC) is an organization of dermatologic surgeons, clinicians and researchers from multiple disciplines dedicated to advancing the care and understanding of skin cancer in organ transplant recipients.
These patients are up to 65 times more likely to develop skin cancer than people without transplants. Skin cancer is the most common cancer affecting solid organ transplant recipients, affecting up to 70 percent of patients within 20 years, and is the result of intense immunosuppressive regimens.
Special message from John Carucci, MD, PhD, ITSCC Immediate Past President
Dear ITSCC Members and Friends:
It is with extreme sorrow that I share the news that our cherished friend and current ITSCC President, Oscar Colegio, passed away unexpectedly this past Saturday at his home. Oscar served in many leadership roles with ITSCC and contributed so much to the culture of the organization through his brilliance, generosity, ingenuity, and humor. Oscar was a gifted scientist, expert clinician, and wonderful teacher who influenced so many up and coming physicians and investigators. Oscar was a builder and there is no telling what he might have achieved in his recent position as Chairman, Department of Dermatology at Roswell Park Cancer Center. Most importantly, Oscar was a devoted husband to his wife, Brenda, and proud father to his sons Austin and Otto. Our thoughts and prayers are with Oscar’s family, friends and colleagues as he will be missed by all.
Your tax-deductible donation supports the education and research of physicians and scientists committed to improving the quality of life of organ transplant recipients. If you are unable to donate online or require other information to make a gift through a trust or other source, email firstname.lastname@example.org for additional assistance. ITSCC's federal tax ID is 43-1964114.
ITSCC is a nonprofit 501(c)(3) organization, and has received support through unrestricted educational grants from pharmaceutical companies and donations of time and funds from physicians, researchers, transplant patients and their families.